Tag
This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor
A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories
In the randomized, double‑blind phase II QUIWI trial, adding quizartinib to standard induction/consolidation chemotherapy and single‑agent maintenance significantly improved event‑free survival and overall survival for adults 18–70 years wi
Applying safety-focused, modernized eligibility criteria to historical AML trials increased patient eligibility from a median of 48% to 84% and reduced racial/ethnic disparities, suggesting pragmatic pathways to improve enrollment and repre
In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups inc
Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.
Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a
A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.
Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against app
The ENHANCE-3 phase 3 trial assessed whether adding magrolimab to venetoclax and azacitidine improves outcomes in untreated AML patients unfit for intensive chemotherapy, finding no survival benefit and a higher rate of fatal adverse events
A major RCT shows intermediate-dose cytarabine is noninferior to high-dose as postinduction therapy in AML, with similar survival and lower toxicity.
